New Huntington's drug shows promise in early safety trial

NCT ID NCT07339514

Ongoing Disease control Sponsor: ExoRNA Bioscience Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests an experimental drug, ER2001, in 27 adults with early Huntington's disease. The main goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo once a week for 6 weeks, with follow-up for 6 months. This is not a cure, but a step toward finding a treatment that may help control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Huntington disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUNTINGTON DISEASE

Contacts and locations

Locations

First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, 510080, China
First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, 510080, China
West China Hospital of Sichuan University

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.